Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
The Lancet. Oncology|November 29, 2008
Part II: Liver function in oncology: towards safer chemotherapy useKathryn M Field, Michael MichaelThe Lancet. Oncology|November 18, 2008
Part I: Liver function in oncology: biochemistry and beyondKathryn M Field, Chris Dow, Michael MichaelJournal of Oncology Practice|September 22, 2010
Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice?Kathryn M Field, Suzanne Kosmider, Michael Jefford, et al.Journal of Oncology Practice|September 22, 2010
Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide surveyKathryn M Field, Suzanne Kosmider, Michael Jefford, et al.Cancer|September 30, 2014
Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversiesKathryn M Field, Justin T Jordan, Patrick Y Wen, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|May 4, 2013
Clinical trial participation and outcome for patients with glioblastoma: multivariate analysis from a comprehensive datasetKathryn M Field, Katharine J Drummond, Merve Yilmaz, et al.Journal of Neuro-Oncology|November 30, 2016
Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatinIwan E Bennett, Kathryn M Field, Christopher M Hovens, et al.Journal of Neuro-Oncology|May 24, 2017
Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastomaKathryn M Field, Madeleine T King, John Simes, et al.Neuro-Oncology Practice|August 7, 2019
Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trialElizabeth J Hovey, Kathryn M Field, Mark A Rosenthal, et al.Cancer|July 6, 2017
The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET)Kathryn M Field, Pramit M Phal, Greg Fitt, et al.Pageof 2